Skip to content

Feasibility study of Epirubicin-Eluting-Bead Embolization for Hepatocellular Carcinoma (JIVROSG-1301)

Feasibility study of Epirubicin-Eluting-Bead Embolization for Hepatocellular Carcinoma (JIVROSG-1301) - Feasibility study of DEB-epiDOX for HCC (JIVROSG-1301)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000013771
Enrollment
8
Registered
2014-04-23
Start date
2014-04-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

arterial embolization with drug eluting beads

Sponsors

Japan Interventional Radiology In Oncology Study Group(IVROSG)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Histologically or clinically diagnosed HCC (excluding the mixed type) 2) No indication for hepatic resection, liver transplantation or local ablative therapy (radiofrequency ablation, etc.) 3) Hypervascular lesion showing enhancement in the early phase on CT or MRI with bolus contrast injection 4) No tumor thrombus in the first branch or main portal vein 5) Eastern Cooperative Oncology Group performance status of 0 to 2 6) Child-Pugh classification of A or B 7) Adequate hematologic, hepatic, renal, and cardiac function; laboratory tests within two weeks before registration in the study are defined as: (1) WBC (2) Platelet count (3) Serum bilirubin 8) Patient age 20 years and above 10) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Prior surgical reconstruction or endoscopic treatment of the biliary tract 2) Clinically significant refractory ascites or pleural effusion 3) Severe arterio-portal or arterio-venous shunts in the liver 4) Allergy to contrast medium that precludes angiography 5) Severe, active co-morbidity, defined as follows: - Uncontrolled cardiac failure, angina and/or rhythm disorders - Myocardial infarction within the last 6 months - Renal failure - Active infection (viral hepatitis is allowed) - Active gastrointestinal bleeding - Other active malignant tumor - Hepatic encephalopathy or severe mental disorder 6) Pregnancy, nursing women, or women of childbearing potential, and men who are sexually active and not willing or able to use medically acceptable forms of contraception 7) Not eligible because of safety issues judged by investigators

Design outcomes

Primary

MeasureTime frame
Response rate

Secondary

MeasureTime frame
Adverse events

Countries

Japan

Contacts

Public ContactHiroaki Ishii

National Cancer Center Hospital Department of Diagnostic Radiology

ishiihiroakii@gmail.com03-5475-5201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026